Comparing two bevifibatide dose regimens for acute ischemic stroke

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-center, randomized, double-blind, dose-response controlled Phase 2 trial comparing a conventional maintenance dose versus a lower maintenance dose of bevifibatide given after standard baseline medications. Participants are adults with acute ischemic stroke (NIHSS ≥ 3) without visible large or medium intracranial vessel occlusion, enrolled within specific early time windows or after early deterioration following IV thrombolysis. The trial's co-primary focus is 90-day neurological outcome and the incidence of symptomatic intracranial hemorrhage, with safety events and serious adverse events monitored closely. The goal is to identify a dosing regimen that preserves anti-platelet benefit while minimizing bleeding risk to inform larger randomized trials.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Any of the following presentations of acute ischemic stroke (AIS): ① Within 24 hours of time last known well and ineligible for intravenous thrombolysis (IVT) or endovascular treatment (EVT). ② More than 24 hours and less than 96 hours after time last known well but within 24 hours of ischemic stroke progression \[worsening of ≥ 2 points on the NIHSS\]; and ineligible for IVT or EVT without ICH confirmed by CT scan or MRI. ③ Treated with IVT followed by early neurological deterioration (worse NIHSS by ≥ 4 points) within the first 24 hours after IVT without ICH confirmed by CT scan or MRI. ④ Treated with IVT followed by no neurological improvement (Neurological improvement is defined as decrease in the NIHSS score by ≥ 2 points) from baseline within 4 to 24 hours after IVT without ICH confirmed by CT scan or MRI.
* NIHSS score ≥ 3 immediately prior to trial entry.
* Without visible large or medium intracranial vessel occlusion on CT angiography (CTA), MR angiography (MRA), or digital subtraction angiography (DSA). (Qualifying mechanisms are: 1. hypoperfusion caused by arterial stenosis; 2. the initial occluded large or medium artery spontaneously recanalized or recanalized with IVT before the vascular imaging performed; 3. multiple or single distal emboli from cardiac or other sources in arterial branches too small to visualized on CTA or MRA; 4. lacunar infarct due to small vessel occlusion).
* Written informed consent obtained from patients or their legal representatives.

Exclusion Criteria:

* CT or MR evidence of intracranial haemorrhage.
* Pre-morbid disability with a mRS score ≥ 2.
* Presence of any of the following unequivocal cardiac sources of embolism: chronic or paroxysmal atrial fibrillation, sick sinus syndrome, mitral stenosis, mechanical valve, endocarditis, intracardiac clot or vegetation, myocardial infarction within three months, dilated cardiomyopathy, left atrial spontaneous echo contrast, ejection fraction less than 30%.
* Planned treatment with dual antiplatelet therapy within 1week of the index stroke.
* Any history of a primary or other intracerebral (parenchymal) haemorrhage (intraventricular, subarachnoid, subdural, epidural).
* Any untreated or incompletely treated intracranial aneurysm, any intracranial vascular malformation or any intracranial tumour.
* Currently pregnant or lactating, and those planned to conceive.
* Subjects with positive urine HCG test results.
* Known allergy to study medication or concomitant medications.
* Gastrointestinal bleeding, urinary tract bleeding, or other major systemic haemorrhage within 30 days.
* Any major surgery within 6 weeks of the index stroke.
* History of heparin-induced thrombocytopenia.
* Expected lifespan less than 3 months.
* Pre-existing neurological or psychiatric disease that would confound the neurological functional outcome evaluations.
* Any of the following laboratory tests: INR \[International Normalized Ratio\]\>2.0, PT\>1.3 times normal value, platelet count\<100 × 109/L, Hb\<10g/dl.
* Systolic pressure greater than 180 mmHg or diastolic pressure greater than 110 mmHg after aggressive treatment.
* Severe renal insufficiency (glomerular filtration rate \< 30 ml/min or serum creatinine \> 220 μmol/L \[2.5 mg/dl\]).
* History of liver dysfunction (AST/ALT exceeding the upper limit of normal by more than twice) or cirrhosis.
* Arterial tortuosity and/or other arterial diseases that prevent the expected internal thrombectomy device from reaching the target vessel.
* Unlikely to be available for 90-day follow-up.
* Current participation in another treatment clinical trial.
* Other conditions that are not suitable for participation in the study.

Where it's running

• Zhujiang Hospital of Southern Medical University
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Study coordinator: Chuanzhi Duan, MD
• Email: doctor_duanzj@163.com
• Phone: 02062782757

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Tegoprazan to prevent GI complications in ischemic stroke patients on antiplatelet therapy

  This trial tests whether tegoprazan can lower gastrointestinal complications in adults with ischemic stroke or TIA who are starting antiplatelet therapy.

  Recruiting at 24 sites Phase 3 Hanyang University · Busan, Busan and 23 other locations · NCT07687706

• Intra-arterial clot-dissolving treatment for medium-vessel ischemic stroke

  The team will test whether giving tenecteplase directly into the artery helps adults with acute ischemic stroke caused by medium-vessel blockage or severe narrowing.

  Recruiting at 6 sites The Second Hospital of Anhui Medical University · Fuyang, Anhui and 5 other locations · NCT07185022

• Endovascular treatment for stroke beyond 24 hours

  This study is testing whether a specific stroke treatment can help people who have had a stroke more than 24 hours ago feel better and regain independence compared to just receiving standard care.

  Recruiting The Second Hospital of Anhui Medical University · Hefei, Anhui · NCT06959199

• Heart assessment to check repeat-stroke risk in people with atrial fibrillation

  This project will test whether detailed heart examinations can find which people with atrial fibrillation who just had an ischemic stroke are at high risk of having another stroke.

  Recruiting Insel Gruppe AG, University Hospital Bern · Bern · NCT06954610

• Portable EEG to triage suspected stroke patients in ambulances

  This trial will test whether a portable dry‑electrode EEG headset (StrokePointer) can detect large vessel occlusion strokes in adults with suspected acute stroke so ambulance crews can take them directly to hospitals that perform thrombectomy.

  Recruiting Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Amsterdam, North Holland · NCT06871969

• Emergency Stroke Unit for treating acute strokes

  This study is testing a new Emergency Stroke Unit that uses a mobile MRI to see if it can help treat stroke patients faster and improve their recovery.

  Recruiting Chinese University of Hong Kong · Hong Kong · NCT06728592

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.